Bernhard Haring

Nov 26, 2024 | onlinelibrary.wiley.com | Bernhard Haring |Michael Bohm

Invited Editorial Considerations on biological age-related therapeutic intensity. Less numbers, more biology Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF Sharmistha Datta Gupta,  Jawad H. Butt,  Eoghan G.M. McMurray,  Atefeh Talebi,  Shingo Matsumoto,  Adel R. Rizkala,  Alasdair D. Henderson,  Akshay S. Desai,  Martin Lefkowitz,  Milton Packer,  Jean L. Rouleau,  Scott D.

Sep 24, 2024 | onlinelibrary.wiley.com | Bernhard Haring |Amr Abdin |Michael Bohm

Invited Editorial Clonal haematopoiesis of indeterminate potential: A new biomarker for heart failure patients? Potential lessons to be learned from cardio-oncology Clonal haematopoiesis is associated with major adverse cardiovascular events in patients with hypertrophic cardiomyopathy Fernando L. Scolari, Darshan Brahmbhatt, Sagi Abelson, Deacon Lee, Raymond H. Kim, Ali Pedarzadeh, Ali Sakhnini, Arnon Adler, Raymond H. Chan, John E.

May 9, 2024 | japscjournal.com | Bernhard Haring |Michael Bohm

Average (ratings) Abstract The role of myocardial revascularisation in patients suffering from ischaemic cardiomyopathy with extensive coronary artery disease and heart failure with reduced ejection fraction (HFrEF) remains controversial. Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are considered revascularisation procedures.

Sep 1, 2023 | tinyurl.com | Bernhard Haring |Rebecca Hunt |Aladdin H Shadyab |Charles B Eaton

References1. "Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in Black Americans". N Engl J Med . 1997;336:466-473. 2. "Transthyretin V122I (pV142I)∗ cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans". Genet Med . 2017;19:733-742. 3. "Transthyretin (TTR) cardiac amyloidosis". Circulation . 2012;126:1286-1300. 4.

Aug 1, 2023 | bmjopen.bmj.com | Daniel Solomon |Leah M. Santacroce |Aladdin H Shadyab |Bernhard Haring

DiscussionPatient-reported outcomes, such as the SF-36, are being used more commonly for clinical decision-making. Individual changes on the SF-36 can help inform and target interventions for at-risk individuals.